Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Oncolytic virus Stories

2013-10-01 12:31:18

CALGARY, Oct. 1, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that abstracts detailing results from two Phase II studies examining the use of REOLYSIN(®) in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumors (REO 016) and in patients with squamous cell carcinoma of the lung (REO 021), are now available on the International Association for the Study...

2013-09-30 04:22:34

THOUSAND OAKS, Calif., Sept. 30, 2013 /PRNewswire/ -- AMGEN (NASDAQ:AMGN) today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). Results of the study's key secondary endpoints will be presented during a poster session at the 17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress in Amsterdam (Abstract No....

2013-09-18 08:28:45

- Primary endpoint achieved while still recruiting SYDNEY, Sept. 18, 2013 /PRNewswire/ -- Viralytics Limited (ASX: VLA, OTCQX: VRACY) has achieved the primary endpoint in its Phase 2 clinical trial of CAVATAK(TM) in the treatment of late stage melanoma patients (the CALM study). The Phase 2 trial is a single arm study being conducted at 10 US sites and is designed to investigate the safety and efficacy of intratumoral CAVATAK(TM) (Coxsackievirus A21) in 54 evaluable(1)...

2013-09-12 23:28:16

Parents do everything they can to protect their children against all of the nasty germs floating around classrooms across the country this time of year. Doctors and researchers at Nationwide Children’s Hospital, however, are looking into how those same types of common viruses can actually help treat a child who is diagnosed with certain cancers. Columbus, Ohio (PRWEB) September 12, 2013 Parents do everything they can to protect their children against all of the nasty germs floating...

2013-09-09 16:24:33

CALGARY, Sept. 9, 2013 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at Baird's 2013 Healthcare Conference on Tuesday September 10(th), 2013 at 8:30 a.m. ET. The conference will take place on September 10(th) and 11(th) in New York, NY at the New York Palace. A live audio link to the Baird webcast presentation will be available at: http://wsw.com/webcast/baird35/ONCY. Dr....

2013-09-09 08:26:34

CALGARY, Sept. 9, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced final tumour response data from its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021). The analysis examined percent best overall tumour responses between pre-treatment and up to six treatment cycles. Of 25...

2013-09-03 08:27:25

SYDNEY, Sept. 3, 2013 /PRNewswire/ -- Viralytics Limited (ASX:VLA, OTCQX:VRACY) has released its financial results for the year ended 30 June 2013. Financial Results Net cash used in operating activities for the Year $3.9 million Cash position at the end of the Year $5.1 million Reported loss $4.1 million Operational Highlights CAVATAK(TM) Phase II CALM Melanoma Clinical Trial (USA) Highlights...

2013-08-27 08:26:48

SYDNEY, Aug. 27, 2013 /PRNewswire/ -- Viralytics Limited (ASX: VLA, OTCQX: VRACY) is pleased to announce that Dr Malcolm McColl, Chief Executive Officer will be presenting at the 15th Annual Rodman & Renshaw Global Investment Conference, Millennium Broadway Hotel, New York. The presentation, on Tuesday September 10, 2013 at 2pm, Eastern US time, will provide a company overview with a focus on the strong interim results from the Phase 2 clinical trial of Viralytics' lead...

2013-08-13 16:26:57

CALGARY, Aug. 13, 2013 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 2013 Wedbush PacGrow Life Sciences Management Access Conference on Wednesday August 14(th), 2013 at 10:20 a.m. ET. The conference will take place on August 13(th) and 14(th) in New York, NY at the Le Parker Meridien Hotel. A live audio link to the webcast presentation is available at:...

2013-08-07 23:23:18

A new type of treatment that pairs neural stem cells with conventional cancer fighting therapies is showing promise in animal studies for the most common and deadliest form of adult brain cancer — glioblastoma multiforme (GBM). The details are revealed in a groundbreaking study led by Maciej Lesniak, M.D., that appears today in STEM CELLS Translational Medicine. Durham, NC (PRWEB) August 07, 2013 A new type of treatment that pairs neural stem cells with conventional cancer fighting...